EP-1231 Immune checkpoint inhibitor and encephalic radiotherapy: Toxicity and Adverse events

Matteucci, Paola; Santo, B.; Ippolito, Edy; Zuccoli, P.; Petrianni, Gian Marco; Trecca, P.; Gentile, Serena; Miele, Martino Tony; Palizzi, S.; Trodella, L.; D’Angelillo, Rolando Maria; Ramella, Sara

doi:10.1016/s0167-8140(19)31651-2

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 45 However, the study had not yet reported the results of the evaluation of cognitive function. 44 Imber et al (2017) found no acute Grade 3–4 AEs or new intracranial bleeding caused by brain RT in neither concurrent group nor sequential group. This study showed that IO combined with high‐dose brain RT was safe as well.…”

Section: Safety and Tolerance Of Rt Combined With ...mentioning

confidence: 98%

“…The timing of RT combined with ICIs may not be a factor for the increase in toxicity 45 . However, the study had not yet reported the results of the evaluation of cognitive function 44 . Imber et al (2017) found no acute Grade 3–4 AEs or new intracranial bleeding caused by brain RT in neither concurrent group nor sequential group.…”

Section: Safety and Tolerance Of Rt Combined With Icismentioning

confidence: 99%

“…Although there was a strong correlation between symptomatic radioactive necrosis (RN) and ICIs in patients with NSCLC treated with SRS‐SRT and newly diagnosed BMs, 42 the AEs are less obvious. Many studies have shown that RT combined with ICIs does not increase the risk of neurotoxicity, 28 , 43 and even this combination rarely presents neurotoxicity 27 , 44 that requires intervention with drugs.…”

Section: Safety and Tolerance Of Rt Combined With ...mentioning

confidence: 99%

See 2 more Smart Citations

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges

et al. 2022

View full text Add to dashboard Cite

At present, whole‐brain radiation therapy/stereotactic radiosurgery is one of the main local treatments for brain metastasis of non‐small‐cell lung cancer (NSCLC). Currently, it has been proved that radiotherapy (RT) can regulate the immune response, and small‐sample studies have shown that patients with NSCLC brain metastases (BMs) can benefit from RT combined with immunotherapy (IO). However, the efficacy and safety of the combination treatment have not been deeply elaborated. Notably, as a challenge that is still being explored, the timing of RT combined with IO is likely to be an important factor affecting efficacy and prognosis. This article reviews the current application and challenges of RT combined with IO from the perspectives of molecular mechanism, combination timing, safety, and efficacy. The purpose is to provide information on clinical evidence‐based medicine of combination between RT with IO. For further investigation, we also discuss the major challenges and prospects of RT combined with IO in NSCLC BMs.

show abstract

Section: Safety and Tolerance Of Rt Combined With ...mentioning

confidence: 98%

Section: Safety and Tolerance Of Rt Combined With Icismentioning

confidence: 99%